Therefore, it has been proposed that PEComas can be subdivided into two molecular subgroups: type 1, which is responsive to mTOR inhibitors, and type 2, which is responsive to c-MET inhibitors. Here, MET is linked to neoplasm with perivascular epithelioid cell differentiation.